Health Care & Life Sciences » Pharmaceuticals | Mereo BioPharma Group PLC

Mereo BioPharma Group PLC | Income Statement

Fiscal year is January-December. All values GBP Thousands.
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
11.40
33.40
36.10
39.50
Gross Income
11.40
33.40
36.10
39.50
SG&A Expense
13,112.80
36,145.90
45,267.80
35,169
EBIT
13,124.20
36,179.30
45,303.80
35,208.40
Unusual Expense
-
-
54.50
273.20
Non Operating Income/Expense
37.20
2,262.60
1,722.50
65.80
Interest Expense
-
-
697.20
2,612
Pretax Income
13,135.60
33,721.60
46,951.10
37,306.10
Income Tax
946.70
5,331.30
8,152.10
5,277.40
Consolidated Net Income
12,189.00
28,390.30
38,799.10
32,028.70
Net Income
12,189.00
28,390.30
38,799.10
32,028.70
Net Income After Extraordinaries
12,189.00
28,390.30
38,799.10
32,028.70
Net Income Available to Common
12,189.00
28,390.30
38,799.10
32,028.70
EPS (Basic)
0.19
0.63
0.56
0.45
Basic Shares Outstanding
64,340.80
44,789.90
69,012.30
71,144.80
EPS (Diluted)
0.19
0.63
0.56
0.45
Diluted Shares Outstanding
64,340.80
44,789.90
69,012.30
71,144.80
EBITDA
13,112.80
36,145.90
45,267.80
35,169
Non-Operating Interest Income
25.70
195.10
826.90
306.80

About Mereo BioPharma Group

View Profile
Address
1 Cavendish Place
London Greater London W1G 0QF
United Kingdom
Employees -
Website http://mereobiopharma.com/
Updated 07/08/2019
Mereo BioPharma Group Plc engages in the acquisition, development, and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases. It focuses on the treatment of patients with Osteogenesis Imperfecta, Alpha-1 Antitrypsin Deficiency, Hypogonadotropic Hypogonadism in obese men, and Acute Exacerbations of Chronic Obstructive Pulmonary Disease. The company was founded by Denise Vera Pollard-Knight, Charles Sermon, Alastair MacKinnon, and John Richard in March 2015 and is headquartered in London, the United Kingdom.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.